Search the Newsreel

Assenagon Asset Management S.A. Decreases Stock Holdings in Vaxcyte, Inc. $PCVX

Assenagon Asset Management S.A. significantly reduced its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 91.3% in the second quarter, selling over 1 million shares and retaining 101,433 shares valued at approximately $5.9 million. Despite this, institutional investors still hold 96.78% of the company's stock. The …

Janus Henderson Group (PCVX) discloses 18.0M-share Vaxcyte ownership stake

Janus Henderson Group Ltd. has disclosed a significant ownership stake in Vaxcyte, Inc. (PCVX), reporting beneficial ownership of 18,040,375 common shares, which represents 12.1% of the outstanding stock as of July 31, 2026. This stake is held through various affiliated asset managers in client …

Vaxcyte, Inc. (PCVX) Stock Analysis: Potential 87.70% Upside with Innovative Vaccine Pipeline

Vaxcyte, Inc. (PCVX) is a biotechnology company focused on developing novel vaccines for bacterial infectious diseases, with a strong pipeline including VAX-24. Despite being unprofitable with a negative P/E and EPS, analysts project an 87.70% upside with an average target price of $109.00, driven …

Vaxcyte Inc (PCVX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Janus Henderson Group (PCVX) discloses 65,694 Vaxcyte shares held for clients

Janus Henderson Group Ltd. filed an amended Schedule 13G, disclosing beneficial ownership of 65,694 shares of Vaxcyte, Inc. common stock, representing a 0.1% stake. These shares are held through its asset management subsidiaries for client accounts, where Janus Henderson has shared voting and dispositive …

The Manufacturers Life Insurance Company Trims Stock Position in Vaxcyte, Inc. $PCVX

The Manufacturers Life Insurance Company reduced its stake in Vaxcyte, Inc. by 20.4% in Q1 2026, selling 22,079 shares but retaining 86,366 shares valued at $5.0 million. Despite this, institutional ownership remains high at 96.8%, with several other major funds increasing their positions. Vaxcyte's …

Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street Zen

Vaxcyte (PCVX) Is Up 8.9% After Completing VAX-31 Phase 3 Enrollment Amid Rising Losses – Has The Bull Case Changed?

Vaxcyte (PCVX) recently reported increased net losses in Q2 2026 but saw its stock rise after completing Phase 3 enrollment for its VAX-31 vaccine. This significant progress in clinical trials, alongside the VAX-A1 study, is critical for the company's future, as investors weigh these …

Vaxcyte, Inc. Q2 2026: Net loss $(284.3M), EPS $(1.97) — 10-Q Summary

Vaxcyte, Inc. reported a Q2 2026 net loss of $(284.3M), or $(1.97) per diluted share, significantly wider than the net loss of $(166.6M), or $(1.22) per diluted share, in Q2 2025. As a clinical-stage vaccine developer with no product sales, the company increased R&D …

FMR LLC (PCVX) discloses 20.8M-share beneficial stake in Vaxcyte common stock

FMR LLC and Abigail P. Johnson have reported an amended beneficial ownership of Vaxcyte Inc. common stock through a Schedule 13G filing. FMR LLC now holds 20,798,906.96 shares, representing 14.4% of the class, with sole voting power over 18,886,452.19 shares and sole dispositive power …

Vaxcyte (NASDAQ:PCVX) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Vaxcyte reports $2.5B cash; Q2 net loss $284.3M, R&D up to $267.9M

Vaxcyte reported its second-quarter 2026 results, showing $2,507.7 million in cash and investments and a net loss of $284.3 million. Research and development expenses increased to $267.9 million, driven by PCV program development. The company also provided updates on its clinical programs, including expected …

Vaxcyte, Inc. SEC Filing (Aug 5, 2026)

This SEC filing for Vaxcyte, Inc. (PCVX) is a Form 144, indicating a proposed sale of 17,000 shares of common stock with an aggregate market value of $935,000. The shares were acquired through the exercise of stock options on August 5, 2026, and are …

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Vaxcyte (Nasdaq: PCVX) announced its Q2 2026 financial results and provided a business update. The company reported approximately $2.5 billion in cash and anticipates topline safety and immunogenicity data from its VAX-31 adult Phase 3 OPUS-1 trial in Q4 2026, with further Phase 3 …

Vaxcyte (Nasdaq: PCVX) posts $605M YTD loss and $2.5B cash balance

PCVX (PCVX) holder plans August 3 sale after option exercise

A holder of Vaxcyte, Inc. (PCVX) common stock, James Wassil, plans to sell 2,250 shares through UBS Financial Services on the NASDAQ on August 3, 2026, after exercising stock options for cash. This planned sale is valued at $121,477.50. The filing also details two …

PCVX (PCVX): insider Andrew Guggenhime plans 10,000-share stock sale

Vaxcyte (PCVX) insider Andrew Guggenhime has filed a Form 144 to sell 10,000 shares of common stock through UBS Financial Services on August 3, 2026, with an indicated value of $539,900. This sale is connected to an exercise of stock options. Guggenhime has made …

Vaxcyte Number of Employees 2026 | Employee Count & Headcount Data

Vaxcyte, Inc. (PCVX) has significantly grown its workforce, reaching 529 employees worldwide as of March 2026, marking a 123.6% increase since 2023. The company is actively hiring, with 73 active job postings in 2026, and its workforce is predominantly located in North America, with …

Liquidity Mapping Around (PCVX) Price Events

This article analyzes Vaxcyte Inc. (PCVX) stock performance, highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents AI-generated trading strategies including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss levels. The analysis emphasizes a significant …

Enterprise value to revenue forward of Vaxcyte, Inc. – FWB:5VA

This article provides the enterprise value to revenue forward metric for Vaxcyte, Inc. (FWB:5VA) on the Frankfurt Stock Exchange. It details that the market is currently closed with no trades recorded. The content is primarily a data point rather than an in-depth analysis.

Grant Pickering (PCVX) outlines 18,198-share sale and recent June stock trades

Grant Pickering, associated with PCVX (Vaxcyte, Inc.), plans to sell 18,198 shares of common stock, valued at approximately $996,704.46, through UBS Financial Services on or about July 27, 2026. This planned sale includes shares resulting from stock option exercises and founder shares. The filing …

Vaxcyte Inc (PCVX) Cash Flow

This article provides a detailed cash flow statement for Vaxcyte Inc (PCVX), including quarterly and annual data for operating, investing, and financing activities. It presents a comprehensive overview of the company's financial movements over several fiscal years and offers definitions for key cash flow …

Vaxcyte Inc (PCVX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Vaxcyte Inc (PCVX), including various indicators and moving averages. It details the signals for MACD, RSI, STOCH, ATR, CCI, Williams %R, TRIX, and StochRSI, as well as several moving averages (MA5, MA10, MA20, MA50, MA100, MA200). The …

Vaxcyte Inc (PCVX) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Vaxcyte Inc (PCVX) focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The current stock price and market capitalization are also presented.

Vaxcyte Inc (PCVX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for Vaxcyte Inc (PCVX), covering volatility, financial risk, and investment risk. It presents various metrics such as Beta, VaR, Maximum Drawdown, Volatility, and Sharpe Ratio across different timeframes. The data aims to help investors understand the potential …

Enterprise value to revenue forward of Vaxcyte, Inc. – BX:PCVX

This article displays the enterprise value to revenue forward for Vaxcyte, Inc. (BX:PCVX) on TradingView. It provides financial data for the company, accessible through the platform's interface. The page serves as a data point for investors and analysts interested in Vaxcyte's valuation metrics.

Vaxcyte, Inc. Revenue Breakdown – NASDAQ:PCVX

This article provides a basic financial overview of Vaxcyte, Inc. (NASDAQ: PCVX) on TradingView. It indicates that the market is closed with no trades and gives access to sections like financials, documents, news, and technical data. The content primarily consists of navigation and boilerplate …

ETFs Investing in Vaxcyte, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Vaxcyte, Inc., a biotechnology company. It presents a comprehensive table detailing each fund's market value, Vaxcyte stock weight, issuer, management style, focus, expense ratio, assets under management (AUM), current price, change percentage, …

Vaxcyte stock consolidates after raising fresh capital and advancing PCVX vaccine pipeline

Vaxcyte stock (PCVX) is consolidating as investors evaluate recent capital raises and progress in its PCVX pneumococcal conjugate vaccine pipeline. The company, which is pre-commercial, reported significant net losses in fiscal 2025 due to high R&D spending, but financing events have extended its cash …

Why (PCVX) Price Action Is Critical for Tactical Trading

This article analyzes Vaxcyte Inc. (PCVX) stock, highlighting a mid-channel oscillation pattern and a significant 50.6:1 risk-reward setup targeting a 14.5% gain against a 0.3% risk. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, alongside multi-timeframe …

PCVX Q1 2026 Earnings: Wider-than-Expected Loss Amid Pipeline Progress - Consensus Forecast Report

Form 4 Vaxcyte Inc For: 16 July By Investing.com

This article reports on a Form 4 filing for Vaxcyte Inc. on July 16, indicating insider transactions. It contextualizes this news with general stock market updates, including technology sector performance, oil prices, and other after-hours movers.

Vaxcyte, Inc. (PCVX) director files Form 3 reporting zero holdings

Vaxcyte, Inc. director Markels John has filed an initial Form 3, indicating he holds zero shares of the company's securities. This filing confirms his beneficial ownership of 0 shares and discloses no purchases, sales, or derivative positions. The Form 3 serves as an initial …